data_1kal_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1kal _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.579 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.579 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.437 ' SG ' ' HB ' ' A' ' 24' ' ' THR . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.437 ' HB ' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.546 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.546 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.8 m120 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.561 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.561 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.494 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.429 ' HG1' ' N ' ' A' ' 7' ' ' ARG . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.429 ' N ' ' HG1' ' A' ' 6' ' ' THR . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.403 ' CB ' ' HG1' ' A' ' 24' ' ' THR . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.402 HG21 HG21 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.527 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.508 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.428 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.41 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.41 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.503 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.407 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.414 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.576 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.576 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.537 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.534 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.517 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.517 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.519 HD21 ' H ' ' A' ' 23' ' ' ASN . 0.0 OUTLIER -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.485 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.485 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.427 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.413 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.413 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' HG23 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.524 HG23 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' TRP . . . . . 0.555 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.555 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.477 ' O ' ' SG ' ' A' ' 17' ' ' CYS . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.613 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.613 ' H ' HH21 ' A' ' 7' ' ' ARG . 0.5 OUTLIER 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.492 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.492 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.579 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.579 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.437 ' SG ' ' HB ' ' A' ' 24' ' ' THR . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.437 ' HB ' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.546 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.546 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.8 m120 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.561 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.561 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.494 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.429 ' HG1' ' N ' ' A' ' 7' ' ' ARG . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.429 ' N ' ' HG1' ' A' ' 6' ' ' THR . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.403 ' CB ' ' HG1' ' A' ' 24' ' ' THR . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.402 HG21 HG21 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.527 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.508 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.428 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.41 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.41 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.503 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.407 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.414 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.576 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.576 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.537 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.534 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.517 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.517 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.519 HD21 ' H ' ' A' ' 23' ' ' ASN . 0.0 OUTLIER -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.485 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.485 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.427 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.413 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.413 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.524 ' SG ' HG23 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.524 HG23 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . 0.555 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.555 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.477 ' O ' ' SG ' ' A' ' 17' ' ' CYS . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.613 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.613 ' H ' HH21 ' A' ' 7' ' ' ARG . 0.5 OUTLIER 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.492 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.492 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.613 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 10' ' ' LEU . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.425 ' HG2' ' N ' ' A' ' 16' ' ' THR . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.587 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.587 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.453 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.422 HG22 ' N ' ' A' ' 29' ' ' CYS . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 28' ' ' THR . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.595 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 28' ' ' THR . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 21' ' ' THR . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.421 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.536 ' CZ3' ' HG3' ' A' ' 3' ' ' PRO . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.536 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.449 ' HB2' ' H ' ' A' ' 21' ' ' THR . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.449 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.431 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 29' ' ' CYS . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.408 ' N ' HG22 ' A' ' 28' ' ' THR . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.535 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.463 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.459 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.426 HG22 ' N ' ' A' ' 29' ' ' CYS . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.426 ' N ' HG22 ' A' ' 28' ' ' THR . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.609 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 16' ' ' THR . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.569 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.451 ' HB ' ' O ' ' A' ' 3' ' ' PRO . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.617 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.617 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 46.3 p-10 -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.411 HG22 ' N ' ' A' ' 29' ' ' CYS . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 28' ' ' THR . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HD3' ' CE3' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.486 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HA ' ' HD2' ' A' ' 7' ' ' ARG . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.486 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.57 HD22 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.464 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.509 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.509 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.546 HG22 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 2' ' ' TRP . . . . . 0.584 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.639 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.639 ' H ' HH21 ' A' ' 7' ' ' ARG . 6.2 m-20 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.449 ' O ' ' HB ' ' A' ' 12' ' ' VAL . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 11' ' ' PRO . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.517 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.517 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.471 ' C ' ' HB2' ' A' ' 17' ' ' CYS . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.401 HG22 ' N ' ' A' ' 29' ' ' CYS . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.401 ' N ' HG22 ' A' ' 28' ' ' THR . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.613 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 10' ' ' LEU . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.425 ' HG2' ' N ' ' A' ' 16' ' ' THR . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.587 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.587 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.453 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.422 HG22 ' N ' ' A' ' 29' ' ' CYS . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 28' ' ' THR . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.595 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 28' ' ' THR . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 21' ' ' THR . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.421 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.536 ' CZ3' ' HG3' ' A' ' 3' ' ' PRO . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.536 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.449 ' HB2' ' H ' ' A' ' 21' ' ' THR . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.449 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.431 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 29' ' ' CYS . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.408 ' N ' HG22 ' A' ' 28' ' ' THR . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.535 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.463 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.459 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.426 HG22 ' N ' ' A' ' 29' ' ' CYS . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.426 ' N ' HG22 ' A' ' 28' ' ' THR . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.609 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 16' ' ' THR . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.569 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.451 ' HB ' ' O ' ' A' ' 3' ' ' PRO . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.617 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.617 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 46.3 p-10 -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.411 HG22 ' N ' ' A' ' 29' ' ' CYS . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 28' ' ' THR . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HD3' ' CE3' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.486 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HA ' ' HD2' ' A' ' 7' ' ' ARG . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.486 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.57 HD22 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.464 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.509 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.509 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.546 HG22 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' TRP . . . . . 0.584 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.639 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.639 ' H ' HH21 ' A' ' 7' ' ' ARG . 6.2 m-20 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.449 ' O ' ' HB ' ' A' ' 12' ' ' VAL . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 11' ' ' PRO . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.517 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.517 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.471 ' C ' ' HB2' ' A' ' 17' ' ' CYS . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.401 HG22 ' N ' ' A' ' 29' ' ' CYS . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.401 ' N ' HG22 ' A' ' 28' ' ' THR . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.613 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 10' ' ' LEU . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.425 ' HG2' ' N ' ' A' ' 16' ' ' THR . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.587 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.587 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.414 HD22 ' N ' ' A' ' 8' ' ' ASN . 1.8 m120 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.453 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.422 HG22 ' N ' ' A' ' 29' ' ' CYS . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 28' ' ' THR . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.595 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 28' ' ' THR . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 21' ' ' THR . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.421 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.536 ' CZ3' ' HG3' ' A' ' 3' ' ' PRO . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.536 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.449 ' HB2' ' H ' ' A' ' 21' ' ' THR . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.449 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.431 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 29' ' ' CYS . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.408 ' N ' HG22 ' A' ' 28' ' ' THR . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.535 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.463 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.459 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.426 HG22 ' N ' ' A' ' 29' ' ' CYS . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.426 ' N ' HG22 ' A' ' 28' ' ' THR . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.609 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 16' ' ' THR . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.569 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.451 ' HB ' ' O ' ' A' ' 3' ' ' PRO . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.617 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.617 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.639 ' H ' HD22 ' A' ' 23' ' ' ASN . 0.0 OUTLIER -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.411 HG22 ' N ' ' A' ' 29' ' ' CYS . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 28' ' ' THR . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HD3' ' CE3' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.486 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HA ' ' HD2' ' A' ' 7' ' ' ARG . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.486 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.57 HD22 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.464 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.509 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.509 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.546 HG22 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' TRP . . . . . 0.584 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.639 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.639 ' H ' HH21 ' A' ' 7' ' ' ARG . 0.5 OUTLIER 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.449 ' O ' ' HB ' ' A' ' 12' ' ' VAL . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 11' ' ' PRO . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.517 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.517 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.471 ' C ' ' HB2' ' A' ' 17' ' ' CYS . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.401 HG22 ' N ' ' A' ' 29' ' ' CYS . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.401 ' N ' HG22 ' A' ' 28' ' ' THR . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 47.4 t . . . . . 0 N--CA 1.498 1.964 1 N-CA-C 88.314 -8.402 . . . . 0.0 88.314 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.613 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.8 t90 -0.46 -70.19 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.414 0 CA-C-O 115.405 -2.236 . . . . 0.0 115.967 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.613 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.2 Cg_endo -98.42 -3.95 0.97 Allowed 'Trans proline' 0 CA--C 1.544 0.977 0 CA-C-N 123.526 2.295 . . . . 0.0 115.864 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -137.71 159.33 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.284 0 N-CA-C 115.016 1.487 . . . . 0.0 115.016 -179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.5 m -97.64 117.01 30.97 Favored 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 105.588 -2.004 . . . . 0.0 105.588 179.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.34 177.09 4.86 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.581 -1.19 . . . . 0.0 112.911 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.62 86.17 2.5 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 100.743 -3.799 . . . . 0.0 100.743 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 53.7 50.62 16.68 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 113.641 -1.618 . . . . 0.0 111.661 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.02 -15.26 48.04 Favored Glycine 0 N--CA 1.488 2.105 0 CA-C-N 113.904 -1.498 . . . . 0.0 115.372 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 91.2 mt -109.66 107.4 59.23 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 10' ' ' LEU . 20.0 Cg_endo -48.72 100.98 0.04 OUTLIER 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.673 2.249 . . . . 0.0 109.349 170.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.8 t -133.82 3.32 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.267 0 O-C-N 124.422 1.076 . . . . 0.0 112.505 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -88.33 -46.39 9.23 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.48 -17.31 31.12 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.425 ' HG2' ' N ' ' A' ' 16' ' ' THR . 35.4 tt0 -96.43 167.24 11.28 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 121.649 0.737 . . . . 0.0 109.02 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 41.8 p -120.3 166.46 13.47 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 113.611 -1.631 . . . . 0.0 112.655 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.2 p -140.78 42.11 1.84 Allowed 'General case' 0 N--CA 1.494 1.728 0 CA-C-N 114.726 -1.125 . . . . 0.0 111.472 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -46.98 -46.16 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 123.799 0.687 . . . . 0.0 110.411 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.24 -34.55 40.69 Favored Glycine 0 N--CA 1.501 3.018 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.73 12.64 4.91 Favored Glycine 0 N--CA 1.486 2.028 0 CA-C-N 112.029 -2.086 . . . . 0.0 113.055 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 50.9 p -143.3 150.66 39.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 118.279 1.04 . . . . 0.0 112.757 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.0 t -115.09 159.33 20.98 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -119.22 35.81 4.7 Favored 'General case' 0 N--CA 1.5 2.03 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.1 m -131.63 83.11 59.11 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.325 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -38.36 111.18 0.1 Allowed 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.899 2.399 . . . . 0.0 110.912 169.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.39 -32.49 2.71 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -104.02 154.11 20.07 Favored 'General case' 0 N--CA 1.484 1.237 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.2 t -113.92 174.25 6.03 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 112.31 -2.223 . . . . 0.0 106.815 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.3 -1.567 0 N-CA-C 116.145 1.905 . . . . 0.0 116.145 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.46 ' O ' ' C ' ' A' ' 2' ' ' TRP . 34.1 t . . . . . 0 N--CA 1.498 1.968 1 N-CA-C 87.019 -8.882 . . . . 0.0 87.019 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.587 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.3 t90 1.45 -71.86 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.352 0 CA-C-O 115.588 -2.148 . . . . 0.0 116.0 -178.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.587 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 16.0 Cg_endo -97.03 -3.89 1.42 Allowed 'Trans proline' 0 C--N 1.317 -1.092 0 CA-C-N 123.594 2.319 . . . . 0.0 115.35 -169.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -137.7 160.08 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 94.2 m -100.35 127.01 46.76 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 104.982 -2.229 . . . . 0.0 104.982 179.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.436 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -117.01 152.33 34.84 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.279 -1.328 . . . . 0.0 113.698 -179.421 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.98 104.01 11.97 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 104.873 -2.269 . . . . 0.0 104.873 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.414 HD22 ' N ' ' A' ' 8' ' ' ASN . 1.8 m120 51.49 40.09 26.08 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 113.388 -1.733 . . . . 0.0 113.804 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 95.06 16.26 41.85 Favored Glycine 0 N--CA 1.496 2.693 0 CA-C-N 114.258 -1.337 . . . . 0.0 114.832 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.5 mt -126.96 95.86 36.03 Favored Pre-proline 0 N--CA 1.486 1.344 0 CA-C-O 116.702 -1.618 . . . . 0.0 108.664 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -50.73 81.56 0.02 OUTLIER 'Trans proline' 0 N--CA 1.508 2.336 0 C-N-CA 123.332 2.688 . . . . 0.0 110.603 171.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.427 ' N ' ' O ' ' A' ' 10' ' ' LEU . 11.0 t -150.44 42.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 CA-C-N 114.175 -1.375 . . . . 0.0 109.912 -179.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 22.9 m -91.69 -28.62 17.33 Favored 'General case' 0 N--CA 1.499 1.99 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.449 179.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 118.38 -31.89 5.44 Favored Glycine 0 N--CA 1.487 2.043 0 O-C-N 124.189 0.931 . . . . 0.0 111.813 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.453 ' HG2' ' H ' ' A' ' 16' ' ' THR . 28.5 tt0 -109.7 173.57 6.26 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-O 122.353 1.073 . . . . 0.0 111.509 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 37.8 p -120.35 166.81 13.03 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 112.908 -1.951 . . . . 0.0 111.933 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 9.5 p -140.88 40.46 1.82 Allowed 'General case' 0 N--CA 1.504 2.255 0 O-C-N 123.776 0.673 . . . . 0.0 112.632 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -46.82 -47.09 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 124.096 0.872 . . . . 0.0 109.862 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -46.27 -35.01 6.55 Favored Glycine 0 N--CA 1.501 3.025 0 O-C-N 125.114 1.508 . . . . 0.0 110.177 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.06 11.81 5.1 Favored Glycine 0 N--CA 1.486 1.978 0 CA-C-N 112.363 -1.918 . . . . 0.0 112.811 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.3 p -150.15 150.24 31.37 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 118.594 1.197 . . . . 0.0 113.719 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.0 t -121.19 -50.38 2.14 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 45.94 55.96 6.51 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 122.914 1.34 . . . . 0.0 110.028 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 64.1 m -126.66 143.69 47.29 Favored Pre-proline 0 N--CA 1.496 1.834 0 CA-C-N 112.68 -2.055 . . . . 0.0 107.964 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -51.94 144.5 35.96 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.349 2.033 . . . . 0.0 111.325 177.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 45.04 18.64 0.14 Allowed Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.738 1.274 . . . . 0.0 114.273 -179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.2 m -126.53 128.73 47.34 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 122.14 0.972 . . . . 0.0 109.027 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.422 HG22 ' N ' ' A' ' 29' ' ' CYS . 6.7 m -113.84 168.83 9.46 Favored 'General case' 0 N--CA 1.49 1.526 0 CA-C-N 112.176 -2.284 . . . . 0.0 106.716 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 28' ' ' THR . 50.6 t . . . . . 0 C--N 1.3 -1.553 0 CA-C-O 123.324 1.535 . . . . 0.0 114.484 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.466 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.7 t . . . . . 0 N--CA 1.495 1.798 1 N-CA-C 87.803 -8.591 . . . . 0.0 87.803 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.595 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.6 t90 2.11 -71.77 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.297 0 CA-C-O 115.215 -2.326 . . . . 0.0 116.543 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 11.6 Cg_endo -98.78 0.06 1.08 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 CA-C-N 123.907 2.431 . . . . 0.0 115.323 -169.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.9 160.61 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 113.288 0.848 . . . . 0.0 113.288 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 96.2 m -99.47 120.23 39.29 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.457 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -122.86 167.34 13.66 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 113.369 -1.741 . . . . 0.0 114.586 -178.988 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 15.9 ttt180 -127.24 100.81 6.23 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 53.78 39.87 30.82 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 122.44 1.114 . . . . 0.0 113.723 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.49 19.31 38.6 Favored Glycine 0 N--CA 1.492 2.388 0 CA-C-N 113.676 -1.602 . . . . 0.0 113.573 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.457 ' N ' ' OG1' ' A' ' 6' ' ' THR . 53.5 mt -123.45 83.81 52.78 Favored Pre-proline 0 N--CA 1.488 1.462 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -50.0 83.42 0.02 OUTLIER 'Trans proline' 0 N--CA 1.506 2.237 0 C-N-CA 124.108 3.205 . . . . 0.0 110.56 168.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 t -147.11 48.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 CA-C-N 113.589 -1.641 . . . . 0.0 109.706 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 57.6 m -105.58 -36.15 7.2 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.165 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.71 -29.86 6.41 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 123.99 0.806 . . . . 0.0 112.41 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -108.42 167.75 9.81 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.551 1.167 . . . . 0.0 110.538 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.6 p -118.77 165.26 14.23 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 112.632 -2.077 . . . . 0.0 110.434 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.0 p -138.32 39.67 2.27 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 119.687 -0.805 . . . . 0.0 113.133 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.9 t -46.8 -46.03 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 123.966 0.791 . . . . 0.0 109.266 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.88 -36.27 3.63 Favored Glycine 0 N--CA 1.501 3.018 0 O-C-N 125.283 1.614 . . . . 0.0 110.004 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 127.68 7.98 4.51 Favored Glycine 0 N--CA 1.485 1.963 0 CA-C-N 112.425 -1.887 . . . . 0.0 114.684 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -159.87 156.19 26.94 Favored 'General case' 0 N--CA 1.502 2.128 0 CA-C-N 119.123 1.461 . . . . 0.0 113.31 -179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 27.4 t -117.63 157.75 25.85 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -132.13 43.8 2.98 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 18.0 p -124.74 141.09 37.09 Favored Pre-proline 0 N--CA 1.496 1.837 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.774 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.63 107.86 2.12 Favored 'Trans proline' 0 N--CA 1.497 1.696 0 C-N-CA 124.251 3.3 . . . . 0.0 112.718 -174.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.22 -0.86 29.72 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 91.4 m -112.19 143.15 43.71 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.821 1.296 . . . . 0.0 111.92 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.1 m -117.08 164.35 14.87 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 111.229 -2.714 . . . . 0.0 104.643 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t . . . . . 0 C--N 1.298 -1.653 0 CA-C-O 123.072 1.415 . . . . 0.0 112.865 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.482 ' O ' ' C ' ' A' ' 2' ' ' TRP . 44.8 t . . . . . 0 N--CA 1.492 1.658 1 N-CA-C 89.609 -7.923 . . . . 0.0 89.609 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.567 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.1 t90 -5.74 -65.48 0.0 OUTLIER Pre-proline 0 N--CA 1.504 2.247 0 N-CA-C 115.761 1.763 . . . . 0.0 115.761 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 15.7 Cg_endo -97.09 -19.05 0.2 Allowed 'Trans proline' 0 C--N 1.32 -0.923 0 C-N-CA 121.846 1.698 . . . . 0.0 116.258 -174.398 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.0 t -129.39 162.86 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 74.0 m -94.84 131.16 41.02 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 28' ' ' THR . 0.0 OUTLIER -124.53 168.52 12.98 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.595 1.331 . . . . 0.0 114.595 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.7 tpt180 -118.9 93.69 4.18 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 49.17 43.34 22.54 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.701 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.24 12.09 37.25 Favored Glycine 0 N--CA 1.495 2.581 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.881 179.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.03 86.14 41.8 Favored Pre-proline 0 N--CA 1.489 1.476 0 CA-C-O 118.363 -0.827 . . . . 0.0 109.793 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -51.24 85.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.116 0 C-N-CA 123.551 2.834 . . . . 0.0 110.861 172.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.03 31.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.43 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 15.9 t -77.37 -45.21 26.71 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 119.28 -15.6 10.81 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 113.114 -1.857 . . . . 0.0 109.063 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -111.31 169.17 8.97 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.729 0.776 . . . . 0.0 109.925 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 59.4 p -119.16 165.41 14.23 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 113.587 -1.642 . . . . 0.0 112.75 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 21' ' ' THR . 9.4 p -147.53 43.18 1.09 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.646 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.58 -26.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 124.063 0.852 . . . . 0.0 112.75 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.55 33.12 6.76 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 124.325 1.016 . . . . 0.0 111.179 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 44.44 56.28 5.6 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 124.189 0.899 . . . . 0.0 112.156 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.421 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 90.0 m -120.13 -73.44 0.65 Allowed 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.502 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 37.9 t 59.44 -73.92 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.42 0 C-N-CA 125.092 1.357 . . . . 0.0 111.096 -179.49 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.5 t30 47.95 51.88 13.8 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 122.285 1.04 . . . . 0.0 113.298 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.502 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 1.5 p -123.52 153.57 66.04 Favored Pre-proline 0 N--CA 1.5 2.071 0 CA-C-N 113.666 -1.606 . . . . 0.0 110.373 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -58.65 143.66 98.37 Favored 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.326 2.018 . . . . 0.0 109.58 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 36.5 28.55 0.02 OUTLIER Glycine 0 N--CA 1.501 3.02 0 O-C-N 125.199 1.562 . . . . 0.0 113.691 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 96.9 m -125.67 125.52 43.21 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.444 HG23 HG23 ' A' ' 6' ' ' THR . 0.0 OUTLIER -112.62 171.89 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 118.514 2.783 . . . . 0.0 118.514 -179.431 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.478 ' O ' ' C ' ' A' ' 2' ' ' TRP . 33.8 t . . . . . 0 N--CA 1.49 1.567 1 N-CA-C 87.244 -8.799 . . . . 0.0 87.244 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.536 ' CZ3' ' HG3' ' A' ' 3' ' ' PRO . 1.4 t90 -0.98 -67.87 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.176 0 CA-C-O 115.794 -2.05 . . . . 0.0 115.792 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.536 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 20.6 Cg_endo -96.69 -13.78 0.46 Allowed 'Trans proline' 0 C--N 1.321 -0.894 0 CA-C-N 122.907 2.074 . . . . 0.0 116.747 -172.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.1 t -130.38 162.48 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.2 m -100.0 131.24 46.08 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 105.212 -2.144 . . . . 0.0 105.212 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -119.65 141.5 49.28 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.041 -1.89 . . . . 0.0 110.237 -179.444 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.38 96.82 9.38 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 50.59 45.72 26.41 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 110.624 -2.989 . . . . 0.0 113.803 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.83 9.16 40.85 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 113.725 -1.579 . . . . 0.0 114.096 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.417 ' N ' ' OG1' ' A' ' 6' ' ' THR . 81.0 mt -120.63 87.65 42.07 Favored Pre-proline 0 N--CA 1.49 1.544 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.236 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -52.61 83.51 0.02 OUTLIER 'Trans proline' 0 N--CA 1.505 2.167 0 C-N-CA 123.845 3.03 . . . . 0.0 113.444 176.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.8 p -163.47 41.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.875 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 43.9 m -97.51 24.92 6.13 Favored 'General case' 0 N--CA 1.502 2.159 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 41.08 21.98 0.05 OUTLIER Glycine 0 N--CA 1.491 2.349 0 CA-C-N 113.128 -1.851 . . . . 0.0 113.856 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 16' ' ' THR . 3.8 tm-20 -139.45 168.44 19.81 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 44.9 p -125.12 161.24 27.26 Favored 'General case' 0 N--CA 1.505 2.325 0 N-CA-C 116.717 2.117 . . . . 0.0 116.717 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.449 ' HB2' ' H ' ' A' ' 21' ' ' THR . 22.2 p -142.26 40.76 1.62 Allowed 'General case' 0 N--CA 1.5 2.073 0 CA-C-N 115.462 -0.79 . . . . 0.0 113.004 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 52.1 t -42.77 -26.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 C-N-CA 123.872 0.869 . . . . 0.0 112.833 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -110.36 36.01 4.51 Favored Glycine 0 N--CA 1.485 1.944 0 O-C-N 124.206 0.941 . . . . 0.0 111.105 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 41.15 62.42 1.78 Allowed Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.449 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 88.5 m -106.5 -60.78 1.61 Allowed 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 117.617 2.451 . . . . 0.0 117.617 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -4.6 -73.95 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.914 0 N-CA-C 115.025 1.491 . . . . 0.0 115.025 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.2 t30 21.04 57.61 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 125.847 1.659 . . . . 0.0 113.319 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.431 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 6.0 t -123.26 145.44 46.38 Favored Pre-proline 0 N--CA 1.499 2.009 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.305 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -57.1 102.65 0.11 Allowed 'Trans proline' 0 N--CA 1.492 1.408 0 C-N-CA 122.988 2.459 . . . . 0.0 111.405 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.59 -48.69 0.96 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.431 ' HB2' ' CG2' ' A' ' 24' ' ' THR . 83.3 m -111.93 131.42 55.39 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 123.482 1.61 . . . . 0.0 111.771 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 29' ' ' CYS . 14.4 m -107.99 169.86 8.35 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 110.795 -2.911 . . . . 0.0 106.098 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.408 ' N ' HG22 ' A' ' 28' ' ' THR . 43.4 t . . . . . 0 C--N 1.302 -1.478 0 CA-C-O 123.548 1.642 . . . . 0.0 114.271 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.489 ' O ' ' C ' ' A' ' 2' ' ' TRP . 35.7 t . . . . . 0 N--CA 1.487 1.383 1 N-CA-C 87.618 -8.66 . . . . 0.0 87.618 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.543 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.2 t90 -2.46 -67.31 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.315 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.535 ' HG3' ' CZ3' ' A' ' 2' ' ' TRP . 22.2 Cg_endo -96.02 -12.88 0.63 Allowed 'Trans proline' 0 C--N 1.32 -0.927 0 CA-C-N 122.109 1.789 . . . . 0.0 116.542 -173.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.3 t -134.39 163.07 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.173 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 13' ' ' CYS . 35.2 m -93.45 123.1 36.53 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.072 -2.195 . . . . 0.0 105.072 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 2.5 t -121.95 170.3 9.94 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 115.724 1.749 . . . . 0.0 115.724 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.463 ' C ' ' HD3' ' A' ' 7' ' ' ARG . 0.1 OUTLIER -132.73 110.38 10.34 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 179.361 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 43.62 36.25 1.19 Allowed 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 122.319 1.057 . . . . 0.0 112.32 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 96.66 28.88 8.57 Favored Glycine 0 N--CA 1.494 2.537 0 CA-C-N 113.647 -1.615 . . . . 0.0 114.716 179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' N ' ' OG1' ' A' ' 6' ' ' THR . 89.1 mt -132.07 82.26 59.56 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -51.49 83.8 0.02 OUTLIER 'Trans proline' 0 N--CA 1.502 2.017 0 C-N-CA 123.351 2.701 . . . . 0.0 111.114 168.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.53 39.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.382 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 5' ' ' CYS . 90.5 m -94.33 -38.78 10.83 Favored 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 119.948 -0.701 . . . . 0.0 109.168 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 123.66 -39.26 2.23 Favored Glycine 0 N--CA 1.49 2.287 0 O-C-N 123.996 0.81 . . . . 0.0 111.937 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.459 ' HG2' ' N ' ' A' ' 16' ' ' THR . 86.2 tt0 -93.38 169.08 10.64 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 122.221 1.01 . . . . 0.0 109.725 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 33.4 p -120.39 166.41 13.59 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.289 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 17.2 p -142.59 39.42 1.54 Allowed 'General case' 0 N--CA 1.496 1.867 0 O-C-N 124.066 0.854 . . . . 0.0 112.488 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.8 t -43.02 -27.26 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 115.736 1.754 . . . . 0.0 115.736 -179.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.35 8.49 62.47 Favored Glycine 0 N--CA 1.497 2.728 0 C-N-CA 120.431 -0.89 . . . . 0.0 115.319 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.39 46.85 4.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 67.1 p -124.92 -141.28 0.29 Allowed 'General case' 0 N--CA 1.493 1.676 0 CA-C-N 114.634 -0.783 . . . . 0.0 110.928 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.451 ' SG ' ' OG1' ' A' ' 24' ' ' THR . 42.7 t 115.7 -70.11 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 C-N-CA 128.867 2.867 . . . . 0.0 108.106 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.1 t30 30.62 52.46 0.13 Allowed 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 125.173 1.389 . . . . 0.0 112.642 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.451 ' OG1' ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -113.51 165.46 13.33 Favored Pre-proline 0 N--CA 1.505 2.297 0 CA-C-N 112.23 -2.259 . . . . 0.0 111.23 179.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_exo -49.12 132.81 28.54 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 123.069 2.512 . . . . 0.0 111.217 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 34.38 32.75 0.02 OUTLIER Glycine 0 N--CA 1.5 2.933 0 O-C-N 125.291 1.619 . . . . 0.0 114.561 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.9 m -124.85 135.32 52.8 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.239 1.019 . . . . 0.0 110.807 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.426 HG22 ' N ' ' A' ' 29' ' ' CYS . 7.3 m -115.11 171.37 7.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 112.315 -2.221 . . . . 0.0 105.926 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.426 ' N ' HG22 ' A' ' 28' ' ' THR . 42.8 t . . . . . 0 C--N 1.303 -1.443 0 CA-C-O 123.882 1.801 . . . . 0.0 115.414 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 2' ' ' TRP . 32.2 t . . . . . 0 N--CA 1.493 1.698 1 N-CA-C 87.434 -8.728 . . . . 0.0 87.434 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.609 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 2.9 t90 2.86 -72.64 0.0 OUTLIER Pre-proline 0 N--CA 1.503 2.216 0 CA-C-O 115.705 -2.093 . . . . 0.0 116.427 -178.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 13.0 Cg_endo -97.7 -0.34 1.44 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 CA-C-N 123.588 2.317 . . . . 0.0 114.724 -168.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.3 t -141.71 158.0 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 -179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.2 m -95.8 122.34 38.48 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 103.581 -2.748 . . . . 0.0 103.581 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.437 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -127.33 165.74 19.14 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 115.274 1.583 . . . . 0.0 115.274 -178.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.9 tpt85 -115.95 92.19 3.83 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 50.88 42.01 27.46 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.47 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.56 13.46 38.02 Favored Glycine 0 N--CA 1.495 2.608 0 CA-C-N 114.467 -1.242 . . . . 0.0 115.339 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.437 ' N ' ' OG1' ' A' ' 6' ' ' THR . 14.0 tp -122.13 91.45 49.0 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -52.65 93.5 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.526 2.151 . . . . 0.0 108.566 171.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 8.5 p -141.42 36.84 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 124.673 1.233 . . . . 0.0 113.453 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.28 -23.28 14.01 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.99 -4.9 78.67 Favored Glycine 0 N--CA 1.484 1.856 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 16' ' ' THR . 40.5 tt0 -119.57 167.8 11.64 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-O 122.128 0.966 . . . . 0.0 112.066 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 72.6 p -120.45 164.12 16.88 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 112.997 -1.91 . . . . 0.0 112.348 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 7.5 p -143.39 41.54 1.48 Allowed 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -41.87 -43.64 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 C-N-CA 124.259 1.024 . . . . 0.0 112.557 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.62 -36.46 85.66 Favored Glycine 0 N--CA 1.496 2.658 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.429 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.34 47.55 0.59 Allowed Glycine 0 N--CA 1.489 2.197 0 CA-C-N 113.211 -1.494 . . . . 0.0 109.584 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 45.7 p -130.19 -141.29 0.23 Allowed 'General case' 0 N--CA 1.497 1.897 0 CA-C-O 118.643 -0.694 . . . . 0.0 111.717 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 t 122.75 -64.1 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.416 0 C-N-CA 129.005 2.922 . . . . 0.0 108.214 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.3 m120 37.59 57.5 1.41 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 124.473 1.108 . . . . 0.0 113.598 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.4 m -117.63 137.3 24.09 Favored Pre-proline 0 N--CA 1.499 2.016 0 CA-C-N 113.139 -1.846 . . . . 0.0 109.192 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -58.96 91.57 0.07 OUTLIER 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.917 3.078 . . . . 0.0 112.633 -175.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.74 -37.92 2.22 Favored Glycine 0 N--CA 1.487 2.092 0 O-C-N 124.07 0.856 . . . . 0.0 111.259 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 32.6 m -100.48 138.37 37.64 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-O 121.995 0.902 . . . . 0.0 110.439 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 t -117.15 -179.75 3.79 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 104.546 -2.391 . . . . 0.0 104.546 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 44.6 t . . . . . 0 C--N 1.302 -1.483 0 N-CA-C 117.189 2.292 . . . . 0.0 117.189 -179.849 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.475 ' O ' ' C ' ' A' ' 2' ' ' TRP . 30.6 t . . . . . 0 N--CA 1.495 1.775 1 N-CA-C 87.539 -8.689 . . . . 0.0 87.539 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.569 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.7 t90 0.59 -69.05 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.324 0 CA-C-O 115.583 -2.151 . . . . 0.0 115.967 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 9.1 Cg_endo -99.39 -8.55 0.44 Allowed 'Trans proline' 0 C--N 1.321 -0.919 0 CA-C-N 123.102 2.143 . . . . 0.0 116.676 -173.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 2.5 t -134.0 158.65 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -92.85 101.5 13.87 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 101.086 -3.672 . . . . 0.0 101.086 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -129.89 -171.64 2.57 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.418 0.628 . . . . 0.0 111.988 -178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.21 83.11 2.01 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 101.512 -3.514 . . . . 0.0 101.512 179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 55.61 43.03 28.91 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-N 112.641 -2.072 . . . . 0.0 111.171 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.86 4.1 39.36 Favored Glycine 0 N--CA 1.488 2.145 0 CA-C-N 114.863 -1.062 . . . . 0.0 112.373 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.0 mt -114.04 87.87 13.69 Favored Pre-proline 0 N--CA 1.494 1.726 0 CA-C-O 118.818 -0.611 . . . . 0.0 112.326 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -40.52 113.91 0.24 Allowed 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.276 2.651 . . . . 0.0 109.834 168.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -125.66 -19.22 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 N-CA-C 115.171 1.545 . . . . 0.0 115.171 -179.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.24 -49.25 5.29 Favored 'General case' 0 N--CA 1.506 2.336 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.633 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.42 4.76 17.42 Favored Glycine 0 N--CA 1.489 2.232 0 O-C-N 124.374 1.046 . . . . 0.0 112.43 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -116.27 178.88 4.16 Favored 'General case' 0 N--CA 1.485 1.285 0 CA-C-O 122.1 0.952 . . . . 0.0 111.941 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.451 ' HB ' ' O ' ' A' ' 3' ' ' PRO . 72.6 p -123.04 163.61 20.15 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 112.148 -2.296 . . . . 0.0 112.55 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.617 ' HB2' ' H ' ' A' ' 21' ' ' THR . 29.6 p -141.98 40.1 1.65 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-N 114.12 -1.4 . . . . 0.0 110.378 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -44.23 -27.88 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 123.945 0.778 . . . . 0.0 112.687 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.09 31.93 7.49 Favored Glycine 0 N--CA 1.49 2.291 0 O-C-N 124.347 1.03 . . . . 0.0 111.681 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.85 63.78 4.7 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 123.607 0.622 . . . . 0.0 112.769 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.617 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 85.2 m -105.58 -84.63 0.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 CA-C-N 113.774 -1.213 . . . . 0.0 114.039 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 17' ' ' CYS . 63.6 m -6.34 99.0 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.495 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.639 ' H ' HD22 ' A' ' 23' ' ' ASN . 0.0 OUTLIER -125.72 52.08 1.68 Allowed 'General case' 0 N--CA 1.499 1.995 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.715 -179.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.0 m -109.95 141.32 23.51 Favored Pre-proline 0 N--CA 1.505 2.295 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.639 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -65.6 102.02 0.48 Allowed 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.836 2.358 . . . . 0.0 109.669 171.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.48 -34.48 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 45.3 m -116.51 116.51 27.76 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.411 HG22 ' N ' ' A' ' 29' ' ' CYS . 21.4 m -106.44 163.31 12.96 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 113.493 -1.685 . . . . 0.0 107.629 -179.322 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 28' ' ' THR . 49.4 t . . . . . 0 C--N 1.3 -1.554 0 CA-C-O 123.09 1.424 . . . . 0.0 113.405 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.488 ' O ' ' C ' ' A' ' 2' ' ' TRP . 48.5 t . . . . . 0 N--CA 1.485 1.296 1 N-CA-C 88.685 -8.265 . . . . 0.0 88.685 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.549 ' CD1' ' C ' ' A' ' 2' ' ' TRP . 1.0 OUTLIER -4.03 -65.89 0.0 OUTLIER Pre-proline 0 N--CA 1.505 2.319 0 CA-C-O 116.515 -1.707 . . . . 0.0 115.6 -179.016 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.525 ' HD3' ' CE3' ' A' ' 2' ' ' TRP . 14.9 Cg_endo -97.09 -18.29 0.23 Allowed 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 116.662 1.755 . . . . 0.0 116.662 -174.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.6 t -130.17 163.69 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 88.3 m -97.67 122.4 40.71 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.735 -1.579 . . . . 0.0 106.735 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.486 ' HG1' ' H ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER -121.81 166.26 14.62 Favored 'General case' 0 N--CA 1.497 1.891 0 CA-C-N 113.862 -1.517 . . . . 0.0 114.941 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HA ' ' HD2' ' A' ' 7' ' ' ARG . 18.1 tpt85 -113.26 104.57 12.46 Favored 'General case' 0 C--N 1.306 -1.286 1 N-CA-C 99.084 -4.413 . . . . 0.0 99.084 179.274 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 36.39 46.86 0.45 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-N 113.833 -1.53 . . . . 0.0 114.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.486 ' H ' ' HG1' ' A' ' 6' ' ' THR . . . 116.02 -21.43 12.21 Favored Glycine 0 N--CA 1.5 2.959 0 N-CA-C 119.939 2.736 . . . . 0.0 119.939 179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.57 HD22 ' N ' ' A' ' 10' ' ' LEU . 1.2 mm? -105.32 114.12 63.7 Favored Pre-proline 0 N--CA 1.487 1.409 0 CA-C-O 116.999 -1.477 . . . . 0.0 110.81 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -60.18 91.64 0.09 OUTLIER 'Trans proline' 0 N--CA 1.501 1.933 0 C-N-CA 123.029 2.486 . . . . 0.0 108.744 175.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.15 40.56 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 CA-C-N 114.535 -1.211 . . . . 0.0 112.499 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.2 t -103.43 -46.19 4.64 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 116.0 -12.13 17.42 Favored Glycine 0 N--CA 1.484 1.843 0 CA-C-N 114.004 -1.453 . . . . 0.0 109.899 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.464 ' HG2' ' N ' ' A' ' 16' ' ' THR . 37.0 tt0 -112.03 168.24 9.75 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 121.766 0.793 . . . . 0.0 110.4 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 69.2 p -121.91 164.0 18.3 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.509 ' HB2' ' H ' ' A' ' 21' ' ' THR . 19.5 p -146.05 42.75 1.22 Allowed 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.076 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -43.09 -25.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.11 18.86 55.05 Favored Glycine 0 N--CA 1.494 2.562 0 O-C-N 124.132 0.895 . . . . 0.0 113.562 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 70.56 50.1 27.46 Favored Glycine 0 N--CA 1.488 2.114 0 CA-C-O 119.596 -0.558 . . . . 0.0 112.35 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.509 ' H ' ' HB2' ' A' ' 17' ' ' CYS . 86.3 m -127.34 -99.74 0.37 Allowed 'General case' 0 N--CA 1.502 2.153 0 N-CA-C 114.713 1.375 . . . . 0.0 114.713 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 24' ' ' THR . 43.7 t 90.83 -59.75 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.293 0 C-N-CA 127.281 2.232 . . . . 0.0 105.342 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 t30 46.55 49.34 13.66 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.546 HG22 ' SG ' ' A' ' 22' ' ' CYS . 0.8 OUTLIER -140.24 118.04 8.28 Favored Pre-proline 0 N--CA 1.501 2.103 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.219 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -61.96 145.24 96.91 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 122.455 2.103 . . . . 0.0 109.339 -170.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.48 -40.0 2.57 Favored Glycine 0 N--CA 1.483 1.784 0 N-CA-C 107.321 -2.312 . . . . 0.0 107.321 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.3 m -103.76 147.31 27.43 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 122.478 1.133 . . . . 0.0 109.623 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.6 m -116.64 166.86 11.63 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 111.895 -2.411 . . . . 0.0 106.108 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.5 t . . . . . 0 C--N 1.302 -1.494 0 N-CA-C 114.923 1.453 . . . . 0.0 114.923 -179.97 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 2' ' ' TRP . 26.4 t . . . . . 0 N--CA 1.491 1.599 1 N-CA-C 88.687 -8.264 . . . . 0.0 88.687 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . 0.584 ' CE2' ' HB3' ' A' ' 3' ' ' PRO . 1.9 t90 0.28 -69.61 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.339 0 N-CA-C 117.368 2.359 . . . . 0.0 117.368 -178.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HB3' ' CE2' ' A' ' 2' ' ' TRP . 15.0 Cg_endo -97.77 -1.84 1.34 Allowed 'Trans proline' 0 C--N 1.321 -0.897 0 CA-C-N 123.191 2.175 . . . . 0.0 115.615 -170.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 16' ' ' THR . 1.4 t -141.5 157.27 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.142 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 99.8 m -93.71 130.28 39.72 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 102.974 -2.972 . . . . 0.0 102.974 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.407 ' OG1' ' N ' ' A' ' 10' ' ' LEU . 1.4 t -126.76 167.94 15.08 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 114.468 -1.242 . . . . 0.0 113.456 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.639 HH21 ' H ' ' A' ' 8' ' ' ASN . 4.1 tpm_? -122.38 98.79 6.09 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 104.973 -2.232 . . . . 0.0 104.973 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.639 ' H ' HH21 ' A' ' 7' ' ' ARG . 0.5 OUTLIER 45.45 36.04 2.24 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 122.367 1.08 . . . . 0.0 113.125 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 26.86 7.1 Favored Glycine 0 N--CA 1.491 2.312 0 CA-C-N 113.23 -1.805 . . . . 0.0 113.208 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.407 ' N ' ' OG1' ' A' ' 6' ' ' THR . 91.0 mt -127.27 75.19 77.19 Favored Pre-proline 0 C--N 1.308 -1.211 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.449 ' O ' ' HB ' ' A' ' 12' ' ' VAL . 37.3 Cg_endo -53.68 121.89 10.33 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 122.165 1.91 . . . . 0.0 108.938 170.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 11' ' ' PRO . 7.4 p 146.2 50.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 126.935 2.647 . . . . 0.0 106.777 -179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -89.2 -25.99 21.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 113.438 -1.71 . . . . 0.0 109.428 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 131.55 -38.35 1.93 Allowed Glycine 0 N--CA 1.484 1.86 0 O-C-N 124.535 1.147 . . . . 0.0 111.326 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.517 ' HG3' ' H ' ' A' ' 16' ' ' THR . 0.9 OUTLIER -120.98 -179.15 3.93 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 122.287 1.041 . . . . 0.0 112.089 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.517 ' H ' ' HG3' ' A' ' 15' ' ' GLU . 46.0 p -115.2 168.25 10.11 Favored 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 113.434 -1.712 . . . . 0.0 111.982 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.477 ' SG ' ' O ' ' A' ' 4' ' ' VAL . 19.7 p -139.6 30.85 2.09 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -41.26 -44.73 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.247 0 O-C-N 123.734 0.646 . . . . 0.0 111.165 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -40.96 -34.67 0.84 Allowed Glycine 0 N--CA 1.505 3.234 0 O-C-N 125.362 1.664 . . . . 0.0 111.76 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.48 23.97 1.64 Allowed Glycine 0 N--CA 1.483 1.792 0 CA-C-N 112.637 -1.781 . . . . 0.0 113.554 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.471 ' C ' ' HB2' ' A' ' 17' ' ' CYS . 0.0 OUTLIER 169.34 159.55 0.05 Allowed 'General case' 0 N--CA 1.507 2.376 0 CA-C-N 118.253 1.026 . . . . 0.0 111.952 -179.887 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 13.1 t -105.11 167.03 9.98 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -127.37 30.73 5.33 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.8 t -132.78 128.88 21.01 Favored Pre-proline 0 N--CA 1.499 1.992 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.241 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -52.22 141.36 49.35 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.947 1.765 . . . . 0.0 109.364 171.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.63 -31.27 8.19 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.8 m -113.38 147.86 36.91 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-O 122.821 1.296 . . . . 0.0 111.193 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.401 HG22 ' N ' ' A' ' 29' ' ' CYS . 3.5 m -117.58 169.9 9.18 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 110.924 -2.853 . . . . 0.0 103.721 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.401 ' N ' HG22 ' A' ' 28' ' ' THR . 44.9 t . . . . . 0 C--N 1.302 -1.457 0 N-CA-C 115.439 1.644 . . . . 0.0 115.439 179.936 . . . . . . . . 1 1 . 1 stop_ save_